RxDoctor Payments Data

Kaitlyn Bennett, NP

Family · Scottsboro, ALNPI 1154910123

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $713 and has fallen 85.2% since, to $105 in 2025.

$1,869in general payments, 2019–2025

Across 113 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$277
  • AbbVie$236
  • Lilly USA, LLC$233
  • Dexcom, Inc.$143
  • Biohaven Pharmaceutical Holding Company Ltd.$124
  • Pfizer$98
  • plus $759 from 17 others

What the payments were for

  • Food & beverage$1,869100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,869 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama →

Medicare billing

Part B allowed, 2024
$31,698
Medicare patients
308
Services billed
1,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide83$2,877
Montelukast Sodium111$1,959
Fluticasone Propionate152$1,947
Mometasone Furoate58$1,866
Levocetirizine Dihydrochloride106$1,147
Ofloxacin22$783
Albuterol Sulfate HfaAlbuterol Sulfate13$331
Mupirocin28$285
Omeprazole26$226
Famotidine25$211
Doxycycline Hyclate29$180
Pantoprazole Sodium20$143

Paid to pharmacies, not to this prescriber.

Other family in Scottsboro

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →